Time to first relapse up to approximately 27 months from first patient in [clinicaltrials_resource:92381693e705df806eb44a35be78c20c]
Subcutaneous SA237
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Time to first relapse up to approximately 27 months from first patient in [clinicaltrials_resource:92381693e705df806eb44a35be78c20c]
Subcutaneous SA237
Bio2RDF identifier
92381693e705df806eb44a35be78c20c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:92381693e705df806eb44a35be78c20c
measure [clinicaltrials_vocabulary:measure]
Time to first relapse
time frame [clinicaltrials_vocabulary:time-frame]
up to approximately 27 months from first patient in
description
Subcutaneous SA237
identifier
clinicaltrials_resource:92381693e705df806eb44a35be78c20c
title
Time to first relapse up to approximately 27 months from first patient in
@en
type
label
Time to first relapse up to ap ...... 81693e705df806eb44a35be78c20c]
@en